GT200500359A - Compuestos organicos - Google Patents

Compuestos organicos

Info

Publication number
GT200500359A
GT200500359A GT200500359A GT200500359A GT200500359A GT 200500359 A GT200500359 A GT 200500359A GT 200500359 A GT200500359 A GT 200500359A GT 200500359 A GT200500359 A GT 200500359A GT 200500359 A GT200500359 A GT 200500359A
Authority
GT
Guatemala
Prior art keywords
organic compounds
substituted
piperidine compounds
renina
disorders
Prior art date
Application number
GT200500359A
Other languages
English (en)
Inventor
Werner Breitenstein
Takeru Ehara
Claus Ehrhardt
Phillipp Grosche
Yuko Hitomi
Atsuko Iwasaki
Takanori Kanazawa
Kazuhide Konishi
Juergen Klaus Maibaum
Keiichi Masuya
Yuki Matsumoto
Nils Ostermann
Masaki Suzuki
Atsushi Toyao
Fumiaki Yokokawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200500359A publication Critical patent/GT200500359A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

ESTA INVENCION COMPRENDE LOS COMPUESTOS DE PIPERIDINA 3,4-SUSTITUIDOS, PARA USO EN ANIMALES DE SANGRE CALIENTE CON FINES TERAPEUTICOS Y/O DE DIAGNOSTICO DE ENFERMEDADES O DESORDENES QUE DEPENDEN DE LA ACTIVIDAD DE LA RENINA. SE DESCRIBE EL COMPUESTO PARA FORMULACIONES FARMACEUTICAS, DE FORMULA GENERAL (I), QUE COMPRENDEN COMPUESTOS DE PIPERIDINA 3,4-SUSTITUIDOS Y METODO PARA SU MANUFACTURA.
GT200500359A 2004-12-30 2005-12-07 Compuestos organicos GT200500359A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0428526.8A GB0428526D0 (en) 2004-12-30 2004-12-30 Organic compounds

Publications (1)

Publication Number Publication Date
GT200500359A true GT200500359A (es) 2006-07-17

Family

ID=34179049

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500359A GT200500359A (es) 2004-12-30 2005-12-07 Compuestos organicos

Country Status (21)

Country Link
US (2) US8084450B2 (es)
EP (2) EP1833816B1 (es)
JP (1) JP5188814B2 (es)
KR (1) KR20070091174A (es)
CN (1) CN101094848B (es)
AR (1) AR052446A1 (es)
AT (1) ATE448217T1 (es)
AU (1) AU2005321475B2 (es)
BR (1) BRPI0519769A2 (es)
CA (1) CA2587348A1 (es)
DE (1) DE602005017665D1 (es)
ES (1) ES2336470T3 (es)
GB (1) GB0428526D0 (es)
GT (1) GT200500359A (es)
MX (1) MX2007008078A (es)
PE (1) PE20061332A1 (es)
PL (1) PL1833816T3 (es)
PT (1) PT1833816E (es)
RU (1) RU2411239C2 (es)
TW (1) TW200635915A (es)
WO (1) WO2006069788A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0505969D0 (en) * 2005-03-23 2005-04-27 Novartis Ag Organic compounds
GB0510810D0 (en) * 2005-05-26 2005-06-29 Novartis Ag Organic compounds
MX2007014722A (es) 2005-05-27 2008-02-15 Actelion Pharmaceuticals Ltd Nuevos derivados de amida de acido piperidin carboxilico.
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
BRPI0620736A2 (pt) 2005-12-30 2011-12-20 Novartis Ag compostos orgánicos
CN101379033A (zh) 2006-02-02 2009-03-04 埃科特莱茵药品有限公司 新颖二级胺
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008093737A1 (ja) 2007-01-31 2008-08-07 Dainippon Sumitomo Pharma Co., Ltd. アミド誘導体
WO2008128832A1 (en) * 2007-04-18 2008-10-30 Nicox S.A. Nitroderivatives of non-peptidic renin inhibitors for the treatment of cardiovascular, renal and chronic liver disease, inflammations and metabolic syndrome
US8343968B2 (en) * 2007-05-24 2013-01-01 Merck Canada Inc. Case of renin inhibitors
TWI452044B (zh) * 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp 嗎啉衍生物
ES2541107T3 (es) 2007-06-25 2015-07-16 Novartis Ag Derivados de N5-(2-etoxietil)-N3-(2-piridinil)-3,5-piperidindicarboxamida para su uso como inhibidores de renina
US8183381B2 (en) 2007-07-19 2012-05-22 Metabolex Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
WO2009057515A1 (ja) * 2007-11-01 2009-05-07 Ube Industries, Ltd. スルホン酸フェニル化合物、それを用いた非水電解液及びリチウム電池
JP5484069B2 (ja) * 2007-12-19 2014-05-07 大日本住友製薬株式会社 二環性へテロ環誘導体
US20110053949A1 (en) * 2008-04-17 2011-03-03 Pfizer Inc. 4-[3-(aryloxy)benzylidene]-3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
WO2009135299A1 (en) * 2008-05-05 2009-11-12 Merck Frosst Canada Ltd. 3, 4 - substituted piperidine derivatives as renin inhibitors
HUE039416T2 (hu) 2008-06-19 2018-12-28 Takeda Pharmaceuticals Co Heterociklusos vegyület és ennek alkalmazása
KR20110026481A (ko) * 2008-06-20 2011-03-15 메타볼렉스, 인코포레이티드 아릴 gpr119 작동약 및 이의 용도
JP2012511514A (ja) * 2008-12-10 2012-05-24 メルク・カナダ・インコーポレイテツド レニン阻害剤としての3,4−置換ピペリジン誘導体
CA2763938C (en) * 2009-06-19 2017-07-11 Basf Se Herbicidal benzoxazinones
AU2010263641A1 (en) 2009-06-24 2012-01-19 Sumitomo Dainippon Pharma Co., Ltd. N-substituted-cyclic amino derivative
TWI472524B (zh) * 2009-09-28 2015-02-11 Actelion Pharmaceuticals Ltd 腎素抑制劑
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
ES2676209T3 (es) 2010-06-23 2018-07-17 Metabolex Inc. Composiciones de 5-etil-2-{4-[4-(4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
PT2687518T (pt) 2011-03-16 2018-01-19 Mitsubishi Tanabe Pharma Corp Composto heterocíclico saturado contendo azoto
US9783513B2 (en) 2012-08-16 2017-10-10 Ohio State Innovation Foundation STAT3 inhibitors and their anticancer use
EP2933248B1 (en) * 2012-09-14 2018-01-31 Mitsubishi Tanabe Pharma Corporation Novel renin inhibitor
WO2014065413A1 (ja) * 2012-10-26 2014-05-01 日本たばこ産業株式会社 トリアゾール・イソオキサゾール化合物およびその医薬用途
FR3002736B1 (fr) * 2013-03-04 2015-06-26 Virbac Composition orale nutritionnelle et medicamenteuse a usage veterinaire
CN103524511A (zh) * 2013-10-21 2014-01-22 南京邮电大学 2,7,12-三溴-5,10,15-三烷基三并咔唑的制备方法
US10292983B2 (en) 2016-08-03 2019-05-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
CN111423411B (zh) * 2020-04-02 2021-04-16 南京生命源医药科技有限公司 一种新型肾素抑制剂
JP7473879B2 (ja) 2020-08-07 2024-04-24 株式会社リコー 画像形成装置およびクリーニング方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278541A (en) * 1966-10-11 Di-substituted-n-alkyl piperidines
US4559337A (en) 1985-02-25 1985-12-17 G.D. Searle & Co. 8-Chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-(alkoxy-containing acyl)hydrazides
TW224941B (es) 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
CZ134296A3 (en) 1993-11-09 1996-12-11 Merck & Co Inc Piperidine, pyrrolidine and hexahydro-1h-azepine derivatives, process of their preparation and pharmaceutical compositions containing thereof
US5721251A (en) * 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
TR199800409T1 (xx) 1995-09-07 1998-05-21 F.Hoffmann-La Roche Ag Kalp ve b�brek yetersizli�inin tedavii�in yeni 4-(oksialkoksifenil)-3-oksi-piperidinler
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1998006691A2 (en) 1996-08-14 1998-02-19 Warner-Lambert Company Low molecular weight dendritic compounds as pharmaceutical agents
JP4066004B2 (ja) * 1997-10-13 2008-03-26 忠弘 大見 上段部材取付けの基準となる孔を有する複数の下段部材の固定方法および固定用治具
JP2002526528A (ja) 1998-10-07 2002-08-20 ジョージタウン ユニヴァーシティー 単量体およびニ量体の複素環、ならびにその治療的使用
WO2000063173A1 (en) 1999-04-14 2000-10-26 F. Hoffmann-La Roche Ag Process for the preparation of substituted piperidines
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
WO2002076440A2 (en) 2001-03-23 2002-10-03 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
JP2004534017A (ja) 2001-04-27 2004-11-11 バーテックス ファーマシューティカルズ インコーポレイテッド Baceのインヒビター
PL204281B1 (pl) 2001-12-20 2009-12-31 Bristol Myers Squibb Co Pochodna α-(N-sulfonamido)-acetamidu jako inhibitor ß-amyloidu oraz kompozycja farmaceutyczna
KR100783863B1 (ko) 2002-04-29 2007-12-10 액테리온 파마슈티칼 리미티드 7-아릴-3,9-디아자바이사이클로(3.3.1)논-6-엔 유도체 및고혈압, 심혈관 질환 또는 신장 질환의 치료에서 레닌저해물질로써 이들의 용도
US20030216441A1 (en) 2002-05-10 2003-11-20 Gwaltney Stephen L. Farnesyltransferase inhibitors
CA2490138A1 (en) 2002-06-27 2004-01-08 Actelion Pharmaceuticals Ltd. Novel tetrahydropyridine derivatives as renin inhibitors
WO2004058727A1 (en) 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
US20040214832A1 (en) 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
AU2004234040A1 (en) 2003-04-28 2004-11-11 Actelion Pharmaceuticals Ltd Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors
EP1620403B1 (en) 2003-04-29 2007-11-28 Actelion Pharmaceuticals Ltd. Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives
EP1622907A1 (en) 2003-04-30 2006-02-08 Actelion Pharmaceuticals Ltd. Azabicyclononene derivatives
CN1780833A (zh) 2003-04-30 2006-05-31 埃科特莱茵药品有限公司 托品烷衍生物及其作为血管紧张肽转化酶抑制剂的应用
KR20060008937A (ko) 2003-04-30 2006-01-27 액테리온 파마슈티칼 리미티드 레닌 억제제로서 3-위치에 헤테로원자를 갖는9-아자비사이클로[3.3.1]논-6-엔 유도체
BRPI0409882A (pt) 2003-05-02 2006-05-23 Actelion Pharmaceuticals Ltd compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
AU2004293177B2 (en) 2003-11-26 2008-10-23 Novartis Ag 4-phenylpiperidine derivatives as renin inhibitors
AR053406A1 (es) 2004-07-09 2007-05-09 Speedel Experimenta Ag Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas
GB0428250D0 (en) 2004-12-23 2005-01-26 Novartis Ag Organic compounds
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PT1833816E (pt) 2010-02-17
BRPI0519769A2 (pt) 2009-02-17
US20090312304A1 (en) 2009-12-17
EP1833816B1 (en) 2009-11-11
CA2587348A1 (en) 2006-07-06
US8178559B2 (en) 2012-05-15
WO2006069788A1 (en) 2006-07-06
TW200635915A (en) 2006-10-16
MX2007008078A (es) 2007-07-24
AU2005321475A1 (en) 2006-07-06
JP2008526701A (ja) 2008-07-24
US20110263560A1 (en) 2011-10-27
US8084450B2 (en) 2011-12-27
DE602005017665D1 (de) 2009-12-24
JP5188814B2 (ja) 2013-04-24
EP1833816A1 (en) 2007-09-19
AR052446A1 (es) 2007-03-21
RU2007129090A (ru) 2009-02-10
CN101094848B (zh) 2013-03-13
KR20070091174A (ko) 2007-09-07
RU2411239C2 (ru) 2011-02-10
EP2177518A1 (en) 2010-04-21
ATE448217T1 (de) 2009-11-15
PL1833816T3 (pl) 2010-04-30
ES2336470T3 (es) 2010-04-13
CN101094848A (zh) 2007-12-26
AU2005321475B2 (en) 2009-11-12
PE20061332A1 (es) 2006-12-27
GB0428526D0 (en) 2005-02-09

Similar Documents

Publication Publication Date Title
GT200500359A (es) Compuestos organicos
GT200600089A (es) Compuestos organicos
ECSP088587A (es) Compuestos de piperidina 3,5-sustituida como inhibidores de renina
SV2007002007A (es) Compuestos de quinolina sustituidos ref. pc 25932a
UY28369A1 (es) Agentes terapéuticos
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
DOP2006000269A (es) Derivados de 4-amino-pirrolotriazina sustituida útiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogénesis
GT200500307A (es) Compuestos quimicos
CY1108937T1 (el) Χρηση της κινασης πρωτεϊνης ν-β
MX2007011009A (es) Compuestos de piperidina 3,4,5-substituidos.
PA8604301A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
DE60325379D1 (de) Zusammensetzung enthaltend 6-Ä3-(1-adamantyl)-4-methoxyphenylÜ-2-naphthanoesäure zur Behandlung dermatologischer Erkrankungen
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
WO2006072589A3 (en) Disubstituted ureas as kinase inhibitors
PE20070541A1 (es) Compuestos y composiciones que comprenden isoindol-imidas
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
UY29253A1 (es) 3-amino-pirazol(3,4b)piridinas como inhibidores de proteintirosinquinasas, su preparación y uso como medicamento
BRPI0519443A2 (pt) composto orgÂnicos
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
BRPI0510024A (pt) compostos e composições como modulares de ppar
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
PA8514901A1 (es) Metabolitos agonistas/antagonistas de estrogeno